ESC 365 - Phase ii trial of pharmacogenetic guided beta-blocker therapy with bucindolol vs. metoprolol for the prevention of atrial fibrillation/flutter in heart failure: GENETIC-AF

HFA Premium Access

Phase ii trial of pharmacogenetic guided beta-blocker therapy with bucindolol vs. metoprolol for the prevention of atrial fibrillation/flutter in heart failure: GENETIC-AF

Session: Late breaking trial II - Chronic heart failure

Topic: Pharmacotherapy

Speaker: Professor W. Abraham (Columbus, US)

Event: Heart Failure 2018

Congress Presentation

Add to my library

About the speaker

Professor William Abraham

The Ohio State University, Columbus (United States of America)

65 presentations

3 followers

11 more presentations in this session

The HF-Wii study: Improving exercise capacity of patients with heart failure through exergaming: Secondary outcomes and per protocol analysis of an international multicenter RCT

Speaker: Professor T. Jaarsma (Linkoping, SE)

Discussion - HF-Wii

Diabetes and obesity in heart failure: a crossroads for prognosis and the efficacy of beta-blockers

Speaker: Professor D. Kotecha (Birmingham, GB)

Discussion - BB-meta-HF

Discussion - GENETIC-AF

Access the full session

Late breaking trial II - Chronic heart failure

Speakers: Professor W. Abraham, Professor T. Jaarsma, Professor D. Kotecha

About the event

Heart Failure 2018

26 May - 29 May 2018

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources

Explore sponsored resources